GlassScriptPhysician profile
Saul J Silver
NPI 1770544264
$4,452.42
in general payments reported to CMS, 2019-2025
21 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $432 · 2021: $448 · 2022: $1,149 · 2023: $563 · 2024: $1,062 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.39 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $888.15 | 2019-2024 | Xarelto |
| Amgen INC. | $577.19 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $576.78 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $435.19 | 2019-2025 | Avvigo Guidance System |
| Impulse Dynamics (USA) INC. | $301.27 | 2022-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $230.10 | 2022-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $192.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $184.71 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $161.15 | 2024 | Xarelto |
| Atricure, INC. | $146.31 | 2024 | |
| Novo Nordisk INC | $139.90 | 2023-2024 | Wegovy, Ozempic |
| Bracco Diagnostics INC. | $136.20 | 2022-2023 | |
| Eko Health, INC. | $116.92 | 2024 | |
| Pfizer INC. | $78.35 | 2019-2025 | |
| Abbott Laboratories | $78.12 | 2021-2023 | Ensite, Mini Trek, Jot Dx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $75.10 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.74 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.66 | 2021 | |
| Abiomed | $19.62 | 2025 | |
| Cardiva Medical, INC. | $17.99 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Heartflow, INC. | $16.09 | 2023 | Ffrct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saul Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.